[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration

Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503. doi: 10.1212/WNL.0b013e31827f0fd1

Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468. doi: 10.3233/JAD-122059

Dickson DW, Bergeron C, Chin SS et al (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946

Josephs KA, Whitwell JL, Ahmed Z et al (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63:204–212. doi: 10.1002/ana.21223

Josephs KA, Duffy JR, Strand EA et al (2012) Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain 135:1522–1536. doi: 10.1093/brain/aws032

Lowe VJ, Curran G, Fang P et al (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58. doi: 10.1186/s40478-016-0315-6

Marquie M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800. doi: 10.1002/ana.24517

Sander K, Lashley T, Gami P et al (2016) Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. doi: 10.1016/j.jalz.2016.01.003

Smith R, Puschmann A, Scholl M et al (2016) 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139:2372–2379. doi: 10.1093/brain/aww163